财信证券给予丸美生物增持评级，投资企业获批国内首张羟基磷酸钙微球医美三类证，“双美融合”战略持续深化

每日经济新闻2025-02-27

每经AI快讯，财信证券02月27日发布研报称，给予丸美生物（603983.SH）增持评级。评级理由主要包括：1）作为新一代再生医美材料，羟基磷灰石市场潜力巨大；2）丸美生物前瞻性布局医美赛道，持续推进“双美”战略，成长空间不断打开。风险提示：市场竞争日益加剧风险；公司战略执行不达预期风险；人才流失风险等。AI点评：丸美生物近一个月获得2份券商研报关注，买入1家。文章来源：每日经济新闻原标题：财信...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2514892518?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-27 07:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2514892518","market":"sh","top_or_hot":-1,"title":"财信证券给予丸美生物增持评级，投资企业获批国内首张羟基磷酸钙微球医美三类证，“双美融合”战略持续深化","media":"每日经济新闻","content":"<div>\n<p>每经AI快讯，财信证券02月27日发布研报称，给予丸美生物（603983.SH）增持评级。评级理由主要包括：1）作为新一代再生医美材料，羟基磷灰石市场潜力巨大；2）丸美生物前瞻性布局医美赛道，持续推进“双美”战略，成长空间不断打开。风险提示：市场竞争日益加剧风险；公司战略执行不达预期风险；人才流失风险等。AI点评：丸美生物近一个月获得2份券商研报关注，买入1家。文章来源：每日经济新闻原标题：财信...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227072951a2556cb9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>财信证券给予丸美生物增持评级，投资企业获批国内首张羟基磷酸钙微球医美三类证，“双美融合”战略持续深化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n财信证券给予丸美生物增持评级，投资企业获批国内首张羟基磷酸钙微球医美三类证，“双美融合”战略持续深化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-27 07:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227072951a2556cb9&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经AI快讯，财信证券02月27日发布研报称，给予丸美生物（603983.SH）增持评级。评级理由主要包括：1）作为新一代再生医美材料，羟基磷灰石市场潜力巨大；2）丸美生物前瞻性布局医美赛道，持续推进“双美”战略，成长空间不断打开。风险提示：市场竞争日益加剧风险；公司战略执行不达预期风险；人才流失风险等。AI点评：丸美生物近一个月获得2份券商研报关注，买入1家。文章来源：每日经济新闻原标题：财信...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227072951a2556cb9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603983","symbol_name":"丸美生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227072951a2556cb9&s=b","article_id":"2514892518","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227072951a2556cb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2514892518","pubTimestamp":1740612437,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"每经AI快讯，财信证券02月27日发布研报称，给予丸美生物（603983.SH）增持评级。评级理由主要包括：1）作为新一代再生医美材料，羟基磷灰石市场潜力巨大；2）丸美生物前瞻性布局医美赛道，持续推进“双美”战略，成长空间不断打开。风险提示：市场竞争日益加剧风险；公司战略执行不达预期风险；人才流失风险等。AI点评：丸美生物近一个月获得2份券商研报关注，买入1家。文章来源：每日经济新闻原标题：财信证券给予丸美生物增持评级，投资企业获批国内首张羟基磷酸钙微球医美三类证，“双美融合”战略持续深化","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"161027":"证券","603983":"丸美生物"},"translate_title":"Caixin Securities gave Marubi Biotech an overweight rating, and the investment company was approved the first domestic calcium hydroxyphosphate microsphere medical aesthetic class III certificate, and the \"double aesthetic integration\" strategy continues to deepen","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"603983":1},"content_text":"每经AI快讯，财信证券02月27日发布研报称，给予丸美生物（603983.SH）增持评级。评级理由主要包括：1）作为新一代再生医美材料，羟基磷灰石市场潜力巨大；2）丸美生物前瞻性布局医美赛道，持续推进“双美”战略，成长空间不断打开。风险提示：市场竞争日益加剧风险；公司战略执行不达预期风险；人才流失风险等。AI点评：丸美生物近一个月获得2份券商研报关注，买入1家。文章来源：每日经济新闻原标题：财信证券给予丸美生物增持评级，投资企业获批国内首张羟基磷酸钙微球医美三类证，“双美融合”战略持续深化","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514892518","isCrawlerRequest":true}